<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - VIGABATRIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>VIGABATRIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive treatment of focal seizures with or without secondary generalisation not satisfactorily controlled with other antiepileptics (under expert supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By rectum</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1 g once daily, alternatively initially 1 g daily in 2 divided doses, then increased in steps of 500 mg every 1 week, adjusted according to response; usual dose 2&#8211;3 g daily; maximum 3 g per day.</li>
              <li class="dose child"><strong>For children 1 month&#8211;2 years</strong><br/>
                Initially 15&#8211;20 mg/kg twice daily (max. per dose 250 mg twice daily), to be increased over 2&#8211;3 weeks to usual maintenance dose, usual maintenance 30&#8211;40 mg/kg twice daily (max. per dose 75 mg/kg twice daily).</li>
              <li class="dose child"><strong>For children 2&#8211;11 years</strong><br/>
                Initially 15&#8211;20 mg/kg twice daily (max. per dose 250 mg twice daily), to be increased over 2&#8211;3 weeks to usual maintenance dose, usual maintenance 30&#8211;40 mg/kg twice daily (max. per dose 1.5 g twice daily).</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 250 mg twice daily, to be increased over 2&#8211;3 weeks to usual maintenance dose, usual maintenance 1&#8211;1.5 g twice daily.</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                Initially 15&#8211;20 mg/kg twice daily (max. per dose 250 mg twice daily), to be increased over 2&#8211;3 weeks to usual maintenance dose, usual maintenance 30&#8211;40 mg/kg twice daily (max. per dose 75 mg/kg twice daily).</li>
              <li class="dose child"><strong>For children 2&#8211;11 years</strong><br/>
                Initially 15&#8211;20 mg/kg twice daily (max. per dose 250 mg twice daily), to be increased over 2&#8211;3 weeks to usual maintenance dose, usual maintenance 30&#8211;40 mg/kg twice daily (max. per dose 1.5 g twice daily).</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 250 mg twice daily, to be increased over 2&#8211;3 weeks to usual maintenance dose, usual maintenance 1&#8211;1.5 g twice daily.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>





      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Consider reduced dose or increased dose interval if eGFR less than 60&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Consider reduced dose or increased dose interval if estimated glomerular filtration rate less than 60&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Visual field defects</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, aggression, agitation, blurred vision, depression, diplopia, dizziness, drowsiness, excitation in children, fatigue, headache, impaired concentration, impaired memory, irritability, nausea, nervousness, nystagmus, oedema, paraesthesia, paranoia, speech disorder, tremor, visual field defects, vomiting, weight gain,
              </p>
              <p>
                <strong>uncommon:</strong> Ataxia, mania, occasional increase in seizure frequency (especially if myoclonic), psychosis, rash,
              </p>
              <p>
                <strong>rare:</strong> Peripheral retinal neuropathy, retinal disorders, suicidal ideation,
              </p>
              <p>
                <strong>veryRare:</strong> Hepatitis, optic atrophy, optic neuritis,
              </p>
              <p>
                <strong>notKnown:</strong> Movement disorders in infantile spasms,
              </p>
        
        
            <section class="advice">
                <h3>Visual field defects</h3>
              <p>About one-third of patients treated with vigabatrin have suffered visual field defects; counselling and <b>careful monitoring</b> for this side-effect are required.</p>
            </section>
            <section class="advice">
              <p>Encephalopathic symptoms including marked sedation, stupor, and confusion with non-specific slow wave EEG can occur<i>rarely</i>&#8212;reduce dose or withdraw.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">rectal</ph> use</h3>
              <p>Dissolve contents of sachet in small amount of water and administer rectally [unlicensed use] .</p>
            </section>
            <section class="directionsForAdministration">
              <p>The contents of a sachet should be dissolved in water or a soft drink immediately before taking.</p><p>Tablets may be crushed and dispersed in liquid.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients and their carers should be warned to report any new visual symptoms that develop.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Vigabatrin for preventing seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/vigabatrin-for-preventing-seizures">www.medicinesforchildren.org.uk/vigabatrin-for-preventing-seizures</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>:</strong>
            Elderly in adults
          </li>
          <li>
            history of behavioural problems
          </li>
          <li>
            history of depression
          </li>
          <li>
            history of psychosis
          </li>
        </ul>
        <ul>
          <li>
            <p>Vigabatrin may worsen absence, myoclonic, tonic and atonic seizures.</p>
          </li>
          <li>
            <p>Vigabatrin is associated with visual field defects. The onset of symptoms varies from 1 month to several years after starting. In most cases, visual field defects have persisted despite discontinuation, and further deterioration after discontinuation cannot be excluded. Product literature advises visual field testing before treatment and at 6-month intervals. Patients and their carers should be warned to report any new visual symptoms that develop and those with symptoms should be referred for an urgent ophthalmological opinion. Gradual withdrawal of vigabatrin should be considered.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Closely monitor neurological function.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Granules not licensed for rectal use.</p><p>Tablets not licensed to be crushed and dispersed in liquid.</p><p>Vigabatrin doses in BNF publications may differ from those in product literature.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of VIGABATRIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,

            <div id="PHP77442"><a href="../medicinalForm/PHP77442.html" data-target="#PHP77442" data-action="load">Tablet</a></div>
            <div id="PHP77448"><a href="../medicinalForm/PHP77448.html" data-target="#PHP77448" data-action="load">Powder</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
